In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO ...
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that ...
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-release tablets Patients reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback